CSF2 and nosocomial infection: On the other hand, granulocyte-macrophage colony-stimulating factor (GM-CSF) therapies have shown an effect to improve symptoms of adult patients with severe sepsis or cirrhosis by restoring innate immune responses [12,13] and pediatric patients with multiple organ dysfunction syndrome (MODS) by preventing nosocomial infection [14].